Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients
Study for Patients with Chronic Lymphocytic Leukemia (CLL) who are Currently Receiving Treatment with Venetoclax
Sponsor: MSKCC
Enrolling: Male and Female Patients
IRB Number: AAAT7380
U.S. Govt. ID: NCT04419519
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out whether people who are currently receiving treatment with venetoclax can stop treatment and remain off-treatment for at least 12 months, if they are free of residual disease (MRD- negative) when they stop treatment.
This study is closed
Investigator
Nicole Lamanna, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with chronic lymphocytic leukemia (CLL)? Yes No
Are you currently receiving treatment with venetoclax? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE